Wiley Open Access, Clinical Case Reports, 9(3), p. 740-743, 2015
DOI: 10.1002/ccr3.333
Full text: Download
Distinguishing chronic lymphoproliferative disorder of NK-cells from aggressive NK-cell leukemia is critical because they have distinct clinical course and management. Immunophenotyping plays a key role in distinguishing these two entities, however, it could not be used as sole criteria and clinical/laboratory findings are equally important.